CIPROBAY 250 TABLET 250 mg

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

CIPROFLOXACIN HYDROCHLORIDE

Available from:

BAYER (SOUTH EAST ASIA) PTE LTD

ATC code:

J01MA02

Dosage:

250 mg

Pharmaceutical form:

TABLET, FILM COATED

Composition:

CIPROFLOXACIN HYDROCHLORIDE 291.0MG

Administration route:

ORAL

Prescription type:

Prescription Only

Manufactured by:

Bayer AG

Authorization status:

ACTIVE

Authorization date:

1989-06-07

Patient Information leaflet

 
Ciprobay Tab & IV  PI_SG_CCDS16_3July2014   
NAME OF THE MEDICINAL PRODUCT 

Ciprobay 250mg film-coated tablets 
Ciprobay 500mg film-coated tablets 
Ciprobay 100 Infusion Solution 100 mg/50 ml 
Ciprobay 200 Infusion Solution 200 mg/100 ml 

QUALITATIVE AND QUANTITATIVE COMPOSITION  

250MG 
Each film-coated tablet contains 250 mg ciprofloxacin as
hydrochloride. 

500MG 
Each film-coated tablet contains 500 mg ciprofloxacin as
hydrochloride. 

100 MG/50 ML 
Each glass bottle
with 50 ml solution for infusion contains 100 mg ciprofloxacin. The sodium 
content is 177 mg (7.7 mmol). 

200 MG/100 ML 
Each glass bottle with 100 ml solution for infusion contains 200 mg ciprofloxacin. The sodium 
content is 354 mg (15.4 mmol). 

PHARMACEUTICAL FORM 

250MG 
Round, nearly white to slightly yellowish
film-coated tablets marked wi
th “CIP score 250” on 
one side and
a “Bayer cross” on the reverse side. The tablet can be divided
into equal halves. 

500MG 
Oblong, nearly white to slightly yellowish film-
coated tablets marked with “CIP score 500” on 
one side and
“BAYER” on the reverse side. The tablet can be divided
into equal halves. 

100 MG/50 ML 
Clear, nearly colourless to slightly yellowish
solution. The pH-value of the solution for infusion 
ranges from 3.9 to 4.5. 

200 MG/100 ML 
Clear, nearly colourless to slightly yellowish
solution. The pH-value of the solution for infusion 
ranges from 3.9 to 4.5. 

INDICATIONS 

Uncomplicated and complicated infections caused by ciprofloxacin
sensitive pathogens. 
Infections of the respiratory tract:  
Ciprofloxacin can be regarded as an advisable treatment for pneumonias caused by _Klebsiella _
spp., _Enterobacter_ spp.,_ Proteus_ spp., _E. coli_,_ Pseudomonas, Haemophilus_ spp._, Moraxella _
_Catarrhalis, Legionel

Summary of Product characteristics

Ciprobay Tab & IV PI_SG_CCDS20_February 2022
NAME OF THE MEDICINAL PRODUCT
Ciprobay 250mg film-coated tablets
Ciprobay 500mg film-coated tablets
Ciprobay 100 Infusion Solution 100 mg/50 ml
Ciprobay 200 Infusion Solution 200 mg/100 ml
QUALITATIVE AND QUANTITATIVE COMPOSITION
250MG
Each film-coated tablet contains 250 mg ciprofloxacin as
hydrochloride.
500MG
Each film-coated tablet contains 500 mg ciprofloxacin as
hydrochloride.
100 MG/50 ML
Each glass bottle with 50 ml solution for infusion contains 100 mg
ciprofloxacin. The sodium
content is 177 mg (7.7 mmol).
200 MG/100 ML
Each glass bottle with 100 ml solution for infusion contains 200 mg
ciprofloxacin. The sodium
content is 354 mg (15.4 mmol).
PHARMACEUTICAL FORM
250MG
Round, nearly white to slightly yellowish film-coated tablets marked
with “CIP score 250” on
one side and a “Bayer cross” on the reverse side. The tablet can
be divided into equal
halves.
500MG
Oblong, nearly white to slightly yellowish film-coated tablets marked
with “CIP score 500” on
one side and “BAYER” on the reverse side. The tablet can be
divided into equal halves.
100 MG/50 ML
Clear, nearly colourless to slightly yellowish solution. The pH-value
of the solution for
infusion ranges from 3.9 to 4.5.
200 MG/100 ML
Clear, nearly colourless to slightly yellowish solution. The pH-value
of the solution for
infusion ranges from 3.9 to 4.5.
INDICATIONS
Uncomplicated and complicated infections caused by ciprofloxacin
sensitive pathogens.
Infections of the respiratory tract:
Ciprofloxacin can be regarded as an advisable treatment for pneumonias
caused by _Klebsiella _
spp., _Enterobacter_ spp.,_ Proteus_ spp., _E. coli_,_ Pseudomonas,
Haemophilus_ spp._, Moraxella _
_Catarrhalis, Legionella_ spp._ and Staphylococcus_.
Infections of the middle ear (otitis media), of the paranasal sinuses
(sinusitis), especially if
these are caused by Gram-negative organisms including _Pseudomonas_ or
by _Staphylococcus. _
Ciprobay Tab & IV PI_SG_CCDS20_February 2022
2
Infections of the eyes
Infection